Published in Biol Psychiatry on May 12, 2006
Genetic regulation of arealization of the neocortex. Curr Opin Neurobiol (2008) 1.51
SNP@Promoter: a database of human SNPs (single nucleotide polymorphisms) within the putative promoter regions. BMC Bioinformatics (2008) 1.17
Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. Neuromolecular Med (2010) 0.94
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Haplotype structure and divergence at human and chimpanzee serotonin transporter and receptor genes: implications for behavioral disorder association analyses. Mol Biol Evol (2010) 0.92
Transcriptional control of the human glucocorticoid receptor: identification and analysis of alternative promoter regions. Hum Genet (2011) 0.89
The role of the serotonergic system at the interface of aggression and suicide. Neuroscience (2013) 0.89
Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry (2012) 0.86
Association of the HTR2A gene with alcohol and heroin abuse. Hum Genet (2013) 0.84
Genetic determinants of UV-susceptibility in non-melanoma skin cancer. PLoS One (2011) 0.84
Pilot study on HTR2A promoter polymorphism, -1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive-compulsive disorder. J Neural Transm (Vienna) (2011) 0.82
5-Hydroxytryptamine (serotonin) 2A receptor gene polymorphism is associated with schizophrenia. Indian J Med Res (2014) 0.81
Individual differences in positivity offset and negativity bias: Gender-specific associations with two serotonin receptor genes. Pers Individ Dif (2013) 0.80
Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population. Psychiatry Investig (2010) 0.80
A pilot study evaluating genetic and environmental factors for postpartum depression. Innov Clin Neurosci (2013) 0.78
Incomplete coverage of candidate genes: a poorly considered bias. Curr Genomics (2007) 0.77
Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients. Int J Clin Exp Pathol (2015) 0.77
Serotonin 5-HT(2A) Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases. Cardiovasc Psychiatry Neurol (2009) 0.77
Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci (2016) 0.75
Serotonin receptor gene (HTR2A) T102C polymorphism modulates individuals' perspective taking ability and autistic-like traits. Front Hum Neurosci (2015) 0.75
An insight into the understanding of 5-HTR2A variants leading to schizophrenia. Indian J Med Res (2014) 0.75
Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA (2010) 13.88
The Collaborative Cross, a community resource for the genetic analysis of complex traits. Nat Genet (2004) 9.37
Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry (2005) 5.72
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry (2012) 3.73
Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry (2005) 3.46
Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry (2011) 3.34
National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med (2010) 3.24
MDDScore: confirmation of a blood test to aid in the diagnosis of major depressive disorder. J Clin Psychiatry (2015) 2.66
NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements (2010) 2.19
Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am J Obstet Gynecol (2012) 2.16
Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry (2007) 2.10
Surface modification to reduce nonspecific binding of quantum dots in live cell assays. Bioconjug Chem (2005) 1.94
Quantitative trait locus analysis using recombinant inbred intercrosses: theoretical and empirical considerations. Genetics (2005) 1.80
Neuron densities vary across and within cortical areas in primates. Proc Natl Acad Sci U S A (2010) 1.78
Signal transduction abnormalities in melancholic depression. Int J Neuropsychopharmacol (2004) 1.73
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry (2007) 1.68
Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol (2009) 1.67
Effort-based decision-making in major depressive disorder: a translational model of motivational anhedonia. J Abnorm Psychol (2012) 1.63
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry (2007) 1.54
Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist (2007) 1.54
Human serotonin transporter variants display altered sensitivity to protein kinase G and p38 mitogen-activated protein kinase. Proc Natl Acad Sci U S A (2005) 1.53
Serotonin and brain development. Int Rev Neurobiol (2004) 1.51
Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord (2005) 1.49
Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior. Proc Natl Acad Sci U S A (2012) 1.48
Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol (2006) 1.47
Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother (2011) 1.45
Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. Br J Psychiatry (2008) 1.44
The current crisis of confidence in antidepressants. J Clin Psychiatry (2011) 1.44
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology (2011) 1.44
Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry (2016) 1.43
A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol Pharmacol (2007) 1.42
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry (2007) 1.40
Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. Proc Natl Acad Sci U S A (2009) 1.38
Genetics of the hippocampal transcriptome in mouse: a systematic survey and online neurogenomics resource. Front Neurosci (2009) 1.36
Genome Reshuffling for Advanced Intercross Permutation (GRAIP): simulation and permutation for advanced intercross population analysis. PLoS One (2008) 1.33
Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res (2008) 1.26
Interactions between Sox10 and EdnrB modulate penetrance and severity of aganglionosis in the Sox10Dom mouse model of Hirschsprung disease. Hum Mol Genet (2004) 1.22
Early- and late-onset startle modulation in unipolar depression. Psychophysiology (2004) 1.20
Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament. Soc Cogn Affect Neurosci (2010) 1.17
A rapid and reliable method of counting neurons and other cells in brain tissue: a comparison of flow cytometry and manual counting methods. Front Neuroanat (2010) 1.14
The relation of patients' treatment preferences to outcome in a randomized clinical trial. Behav Ther (2007) 1.10
Two aspects of the therapeutic alliance: differential relations with depressive symptom change. J Consult Clin Psychol (2011) 1.08
Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol (2007) 1.08
A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol (2007) 1.08
Amygdala temporal dynamics: temperamental differences in the timing of amygdala response to familiar and novel faces. BMC Neurosci (2009) 1.06
Early adverse events, HPA activity and rostral anterior cingulate volume in MDD. PLoS One (2009) 1.06
Depressive realism and clinical depression. Behav Res Ther (2009) 1.05
Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res (2005) 1.04
Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology (2005) 1.04
The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl) (2010) 1.04
Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) (2002) 1.01
Impact of RNA editing on functions of the serotonin 2C receptor in vivo. Front Neurosci (2010) 1.01
A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology (2002) 1.00
Using gene expression databases for classical trait QTL candidate gene discovery in the BXD recombinant inbred genetic reference population: mouse forebrain weight. BMC Genomics (2008) 0.99
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. Biol Psychiatry (2007) 0.99
5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice. Neurosci Res (2006) 0.99
Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins. J Neurochem (2004) 0.98
Identifying suicidal behavior among adolescents using administrative claims data. Pharmacoepidemiol Drug Saf (2013) 0.98
Quantitative trait mapping in a diallel cross of recombinant inbred lines. Mamm Genome (2005) 0.98
Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry (2006) 0.96
5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J Pharmacol Exp Ther (2006) 0.96
Predictors of patient cognitive therapy skills and symptom change in two randomized clinical trials: the role of therapist adherence and the therapeutic alliance. J Consult Clin Psychol (2012) 0.94
Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1. J Biol Chem (2003) 0.93
High-throughput multiplexed transcript analysis yields enhanced resolution of 5-hydroxytryptamine 2C receptor mRNA editing profiles. Mol Pharmacol (2010) 0.93
The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry (2008) 0.92
Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord (2004) 0.92
Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry (2007) 0.91
RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA. Mol Pharmacol (2004) 0.91
A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol Pharmacol (2005) 0.91
His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol (2004) 0.90
Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust N Z J Psychiatry (2012) 0.90
Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. Neuropharmacology (2007) 0.90
Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. J Affect Disord (2013) 0.90
Heritable variation of ERBB2 and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 0.89
Crisis of confidence: antidepressant risk versus benefit. J Clin Psychiatry (2011) 0.89
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry (2007) 0.89
Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. Brain Res Mol Brain Res (2003) 0.88
Use of flow cytometry for high-throughput cell population estimates in brain tissue. Front Neuroanat (2012) 0.87
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. J Affect Disord (2008) 0.87
Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost (2007) 0.87
Oxidative stress and glutathione response in tissue cultures from persons with major depression. J Psychiatr Res (2012) 0.86
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry (2011) 0.86
Inappropriate choice of the experimental unit leads to a dramatic overestimation of the significance of quantitative trait loci for prepulse inhibition and startle response in recombinant congenic mice. Neuropsychopharmacology (2003) 0.85
Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. Neuropsychopharmacology (2004) 0.85
Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf (2012) 0.84
Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene. Head Neck (2011) 0.84
Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother (2010) 0.84
Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials (2013) 0.84
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. J Affect Disord (2010) 0.84
5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide. J Pharmacol Exp Ther (2006) 0.83
Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behav Res Ther (2013) 0.83